证券代码：300832 证券简称：新产业 公告编号：2025-078 鉴于张敏女士辞职将导致公司独立董事成员人数少于董事会成员总人数的 三分之一，且相关董事会专门委员会中独立董事所占比例不符合规定，根据《公 司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》及《公司章程》等有关规定，公司需补选独立董事，在公司股东会选举产 生新任独立董事填补其空缺前，张敏女士将继续按照相关规定履行职责。公司将 按法定程序尽快完成独立董事的补选工作。 张敏女士自 2024 年 9 月 9 日起担任公司独立董事，原定任期至 2027 年 9 月 8 日，截至本公告披露日，张敏女士未持有公司股份，亦不存在应当履行而未 履行的承诺事项。张敏女士在担任公司独立董事期间，恪尽职守、勤勉尽责，认 真审议了董事会及董事会专门委员会各项议案，履行了独立董事的应尽职责，维 护了公司和全体股东的合法权益，为董事会科学决策、公司规范运作和健康发展 发挥了积极作用。公司董事会对张敏女士为公司发展做出的贡献表示衷心的感谢！ 特此公告。 深圳市新产业生物医学工程股份有限公司 董事会 深圳市新产业生物医学工程股份有限公司 关于 ...

Group 1 - The overall revenue and net profit of the IVD sector in A-share listed companies declined in Q2 2025, with a year-on-year decrease of 10.3% in revenue and 18.4% in net profit [2] - The gross profit margin for the sector slightly decreased to 57.3% in Q2 2025, attributed to the impact of medical reform policies such as DRG/DIP payment reforms [2][3] Group 2 - The medical reform has led to a decline in IVD product prices, creating a significant opportunity for domestic companies to replace imports [3] - Companies like Mindray and New Industries are experiencing revenue declines but are positioned to capture market share due to their relatively low market penetration in key segments [3] - The international IVD market presents substantial growth potential, being 4-5 times larger than the Chinese market, with emerging markets like China, India, Turkey, Russia, and Brazil showing rapid growth [4]

Core Viewpoint - The completion of the high-standard factory buildings in the Wuxi Lianyungang Specialized, Refined, Characteristic, and Innovative Industry Park marks a transition from construction to the phase of attracting projects for renovation [1] Group 1: Project Overview - The Wuxi Lianyungang Specialized, Refined, Characteristic, and Innovative Industry Park covers an area of approximately 367 acres with a total investment of about 3.5 billion [1] - The completed high-standard factory consists of 5 buildings with a total construction area of approximately 60,000 square meters, designed to meet the production needs of various enterprises [1] Group 2: Current Status and Future Plans - The high-standard factory has already shown initial success in attracting tenants, with projects in high-end equipment manufacturing, new-generation information technology, and new energy having signed agreements to settle in [1] - The park has completed the filing for factory buildings 6 to 10 and is actively promoting the filing for the remaining buildings to facilitate the park's opening by the end of this year [1] Group 3: Strategic Focus - The park adheres to the principles of "resource sharing, complementary advantages, and collaborative development," focusing on attracting specialized and innovative industries [1] - Notable projects such as Guoxia Technology, Wanda Xilian Meihua Commercial Plaza, and others have signed agreements to settle in, contributing to the establishment of a concentrated cluster of high-tech enterprises and advanced manufacturing industries [1]

Group 1 - A new private equity investment fund named Beijing Beigong Science and Technology Innovation Equity Investment Fund Partnership has been established with a total investment of 300 million yuan [1] - The fund is managed by Beijing Guorong Chuangyin Private Fund Management Co., Ltd., focusing on private equity investment fund management and venture capital fund management services [1] - The partners of the fund include Beijing Innovation Industry Investment Co., Ltd., Beijing Industrial Development Investment Management Co., Ltd., and Beijing Guorong Chuangyin Private Fund Management Co., Ltd. [1]

Core Viewpoint - Meili Technology is actively expanding into the humanoid robot spring market, leveraging its extensive experience in the spring industry to develop high-precision, high-strength springs that enhance the performance of robots [2][5][6]. Group 1: Company Background and Development - Founded 35 years ago, Meili Technology started as a small spring workshop in Zhejiang, initially producing springs for fire extinguishers and later expanding into motorcycle and automotive springs [3][5]. - The company has accumulated significant experience in the spring industry, which supports its entry into new sectors such as the automotive air suspension spring market and humanoid robotics [3][5]. Group 2: Technological Advancements - Meili Technology has established a dedicated robotics team from its pool of over 120 R&D personnel, successfully launching small batches of robot springs within three months [2][5]. - The company is focusing on developing air suspension springs for new energy vehicles, a technology previously dominated by foreign companies, and has successfully created a prototype that passed customer validation [5][6]. Group 3: Market Opportunities - The rapid growth of the domestic new energy vehicle market presents a significant transformation opportunity for Meili Technology, prompting the company to pursue higher technical barriers in its product offerings [5]. - The company anticipates that the added value of robot springs could lead to a new billion-dollar market segment, indicating strong future growth potential [6].

Group 1 - The core point of the article is that New Industry (SZ 300832) has received a patent for a small molecule detection method and kit aimed at eliminating differences in serum and plasma sample testing [1] - As of the first half of 2025, New Industry's revenue composition shows that in vitro diagnostics account for 99.84% of total revenue, while other businesses contribute only 0.16% [1] - The current market capitalization of New Industry is 48.9 billion yuan [1]

Core Insights - The Jiangsu Changzhou Jintan Cultural Industry Promotion Conference was held in Shanghai, highlighting Jintan's strategic location and its integration into major regional development plans [1] - Jintan has focused on developing its cultural industry, emphasizing the integration of culture, commerce, sports, and tourism, and exploring new economic avenues such as the "pet economy" and "camping economy" [1] - The region has achieved significant recognition, ranking 30th among national districts for high-quality development and 62nd for investment potential [1] Group 1 - Jintan has established a "Five New Industries" system focusing on new energy, new infrastructure, new materials, new medicine, and new intelligent equipment, with 669 enterprises projected for 2024, accounting for over 85% of the industrial enterprises [2] - The total industrial output value for the "Five New Industries" is expected to reach 2129.1 billion yuan, representing over 90% of the total industrial output [2] - Jintan has nurtured 8 listed companies, quadrupling the number from ten years ago, with significant growth in the capital market presence [2] Group 2 - The promotion conference resulted in multiple key cultural industry projects being signed, including the integration of agriculture and tourism, professional sports events, and music-related projects [2] - Jintan officials conducted visits to key cultural enterprises in Shanghai to learn from advanced practices and consider differentiated strategies for cultural industry development [2]

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

证券代码：300832 证券简称：新产业 公告编号：2025-077 深圳市新产业生物医学工程股份有限公司 授权公告日：2025年10月17日 上述专利保护技术为公司自主研发，本发明应用于小分子夹心法检测平台， 在该平台上使用了包含特定金属螯合物、表面活性剂和缓冲液的样本稀释液，有 效控制了血清与血浆样本检测结果的一致性，从而显著提升检测的准确性。 本次取得的发明专利不会对公司目前的经营状况产生重大影响，但有利于完 善公司知识产权体系，进一步提升公司软实力。 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 国家知识产权局颁发的1项《发明专利证书》，现将本次取得的发明专利具体情 况公告如下： 发明名称：消除血清血浆样本检测差异的小分子检测方法及试剂盒 中国专利号：ZL202311860257.X 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：张云、李婷华、罗春、刘来壮、易昊禹、李凌 专利申请日：2023年12月31日 2025 年 10 月 22 日 1 ...

Core Insights - The article emphasizes the role of sports events as a powerful engine for urban development, particularly in Guangdong province, where the 15th National Games and the Special Olympics will be held in the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1: Chess and Cultural Development in Chaozhou - Chaozhou, known as the "Hometown of Go," has integrated Go into its cultural identity, with over 20,000 youth participating in Go learning annually [2][4] - The establishment of the Chaozhou Go Association in 1986 marked the beginning of a cultural exchange and promotion of Go, leading to Chaozhou being recognized as a "National Go Hometown" in 2014 [3] - The city has hosted numerous national and provincial Go events, enhancing its cultural brand and aiming to increase its national visibility through the upcoming sports events [5] Group 2: Traditional Industries and Innovation - Chaozhou's traditional industries, particularly ceramics, are undergoing transformation through intelligent manufacturing, with a focus on innovation to overcome high energy consumption and low value-added challenges [6] - The ceramic industry is a key pillar, with Chaozhou being one of the largest sanitary ceramics production bases in China, housing nearly 1,500 registered market entities [6] - The city aims to enhance its smart manufacturing capabilities, targeting an 80% digital coverage rate among enterprises by 2027 [7][8] Group 3: Emerging Industries and Economic Growth - Chaozhou is actively promoting emerging industries such as new materials, renewable energy, and biomedicine, with significant growth in the tea and food sectors, achieving over 20% annual growth in tea production value [8][9] - The establishment of the Cap Biomedical Science Park exemplifies Chaozhou's commitment to developing its biomedical sector, with a production capacity of 50 million test kits annually [9] - The collaboration with Shenzhen aims to leverage resources for mutual growth, transitioning Chaozhou from a manufacturing base to a high-tech manufacturing hub [8][9]